Goldman Sachs Group Inc. Grows Position in Aspen Aerogels, Inc. $ASPN

Key Points

• Goldman Sachs Group Inc. significantly increased its stake in Aspen Aerogels by 89.7%, acquiring an additional 602,586 shares in the first quarter, totaling 1,274,356 shares owned.
• Aspen Aerogels has seen a mixed analyst outlook, with price targets ranging from $10.00 to $19.50, and varying ratings from "Strong Buy" to "Sell".
• The company's most recent earnings report indicated a negative net margin of 78.53% and a revenue decline of 33.8% year-over-year, despite beating EPS estimates.

Goldman Sachs Group Inc. grew its holdings in shares of Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) by 89.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,274,356 shares of the construction company's stock after purchasing an additional 602,586 shares during the quarter. Goldman Sachs Group Inc. owned approximately 1.55% of Aspen Aerogels worth $8,143,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Aspen Aerogels by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 4,373,159 shares of the construction company's stock worth $27,944,000 after acquiring an additional 12,913 shares in the last quarter. Needham Investment Management LLC lifted its position in Aspen Aerogels by 14.5% in the first quarter. Needham Investment Management LLC now owns 2,737,200 shares of the construction company's stock worth $17,491,000 after buying an additional 347,500 shares during the last quarter. AWM Investment Company Inc. lifted its position in Aspen Aerogels by 102.6% in the first quarter. AWM Investment Company Inc. now owns 2,449,221 shares of the construction company's stock worth $15,651,000 after buying an additional 1,240,535 shares during the last quarter. Millennium Management LLC increased its stake in Aspen Aerogels by 4,757.8% in the fourth quarter. Millennium Management LLC now owns 1,622,022 shares of the construction company's stock worth $19,270,000 after purchasing an additional 1,588,632 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in Aspen Aerogels in the fourth quarter worth $13,122,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Aspen Aerogels Price Performance

Shares of ASPN stock traded down $0.07 during trading hours on Friday, hitting $6.92. 528,317 shares of the company's stock were exchanged, compared to its average volume of 1,970,099. The company has a quick ratio of 3.31, a current ratio of 3.98 and a debt-to-equity ratio of 0.34. Aspen Aerogels, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $30.24. The firm has a market cap of $569.52 million, a P/E ratio of -1.81 and a beta of 2.65. The firm has a 50 day moving average of $7.11 and a two-hundred day moving average of $6.47.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The construction company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.08. The firm had revenue of $78.02 million during the quarter, compared to analysts' expectations of $72.53 million. Aspen Aerogels had a positive return on equity of 2.92% and a negative net margin of 78.53%.The firm's revenue for the quarter was down 33.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.21 earnings per share. Aspen Aerogels has set its FY 2025 guidance at -3.860--3.730 EPS. Sell-side analysts forecast that Aspen Aerogels, Inc. will post 0.17 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Barclays downgraded Aspen Aerogels from an "equal weight" rating to an "underweight" rating and lifted their price objective for the company from $7.00 to $16.00 in a report on Monday, August 11th. Canaccord Genuity Group dropped their price target on Aspen Aerogels from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aspen Aerogels has an average rating of "Moderate Buy" and an average target price of $19.50.

Insider Buying and Selling at Aspen Aerogels

In related news, CAO Santhosh P. Daniel sold 4,410 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $7.31, for a total transaction of $32,237.10. Following the transaction, the chief accounting officer owned 19,879 shares of the company's stock, valued at approximately $145,315.49. This represents a 18.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.30% of the company's stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.